Literature DB >> 15325020

Synergistic effects of vascular IL-17 and TNFalpha may promote coronary artery disease.

Anna Csiszar1, Zoltan Ungvari.   

Abstract

Interleukin (IL)-17 is a pro-inflammatory cytokine originally described in T lymphocytes. Increased production of IL-17 has been linked to the induction of cytokines, chemokines and adhesion molecules in various cell types, effects that likely contribute to a number of inflammatory diseases including rheumatoid arthritis. Importantly, in the same pathophysiological conditions production of TNFalpha is also up-regulated and recent studies suggest that cellular signaling pathways induced by IL-17 and TNFalpha converge. Recent studies showed that vascular endothelial and/or smooth muscle cells also express TNFalpha and IL-17, which can be up-regulated in pro-atherogenic pathophysiological conditions in the coronary arteries. TNFalpha has been shown to exert pro-inflammatory vascular effects (e.g., induction of oxidative stress, endothelial apoptosis, up-regulation of adhesion molecules and chemokines), however, the role of vascular IL-17 and its interaction with TNFalpha is much less understood. We propose that increased vascular IL-17 and TNFalpha levels can act synergistically to create a pro-inflammatory microenvironment promoting the development of atherosclerotic vascular disease. Copyright 2004 Elsevier Ltd.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15325020     DOI: 10.1016/j.mehy.2004.03.009

Source DB:  PubMed          Journal:  Med Hypotheses        ISSN: 0306-9877            Impact factor:   1.538


  10 in total

1.  Increased Th17 cell frequency concomitant with decreased Foxp3+ Treg cell frequency in the peripheral circulation of patients with carotid artery plaques.

Authors:  Zhen-dong Liu; Lin Wang; Fang-hong Lu; Hui Pan; Ying-xin Zhao; Shu-jian Wang; Shang-wen Sun; Cui-ling Li; Xiao-liang Hu
Journal:  Inflamm Res       Date:  2012-06-23       Impact factor: 4.575

2.  Interleukin-17 causes Rho-kinase-mediated endothelial dysfunction and hypertension.

Authors:  Hoanglan Nguyen; Valorie L Chiasson; Piyali Chatterjee; Shelley E Kopriva; Kristina J Young; Brett M Mitchell
Journal:  Cardiovasc Res       Date:  2012-12-21       Impact factor: 10.787

3.  Interleukin-17 and interferon-gamma are produced concomitantly by human coronary artery-infiltrating T cells and act synergistically on vascular smooth muscle cells.

Authors:  Raymond E Eid; Deepak A Rao; Jing Zhou; Sheng-fu L Lo; Hooman Ranjbaran; Amy Gallo; Seth I Sokol; Steven Pfau; Jordan S Pober; George Tellides
Journal:  Circulation       Date:  2009-03-02       Impact factor: 29.690

Review 4.  Vascular biology of ageing-Implications in hypertension.

Authors:  Adam Harvey; Augusto C Montezano; Rhian M Touyz
Journal:  J Mol Cell Cardiol       Date:  2015-04-17       Impact factor: 5.000

5.  Elevated frequencies of circulating Th22 cell in addition to Th17 cell and Th17/Th1 cell in patients with acute coronary syndrome.

Authors:  Lei Zhang; Ting Wang; Xiao-qi Wang; Rui-zhi Du; Kai-ning Zhang; Xin-guang Liu; Dao-xin Ma; Shuang Yu; Guo-hai Su; Zhen-hua Li; Yu-qing Guan; Nai-li Du
Journal:  PLoS One       Date:  2013-12-03       Impact factor: 3.240

Review 6.  Ixekizumab for the Treatment of Psoriasis: A Review of Phase III Trials.

Authors:  Benjamin Farahnik; Kourosh Beroukhim; Tian Hao Zhu; Michael Abrouk; Mio Nakamura; Rasnik Singh; Kristina Lee; Tina Bhutani; John Koo
Journal:  Dermatol Ther (Heidelb)       Date:  2016-02-24

7.  Serum Cytokine Profile in Relation to the Severity of Coronary Artery Disease.

Authors:  Xiaoyan Min; Miao Lu; Su Tu; Xiangming Wang; Chuanwei Zhou; Sen Wang; Sisi Pang; Jin Qian; Yiyue Ge; Yan Guo; Di Xu; Kejiang Cao
Journal:  Biomed Res Int       Date:  2017-03-02       Impact factor: 3.411

8.  Interleukin 17A in Patients With Stable Coronary Artery Disease: Are There Differences According to Gender?

Authors:  Dinaldo Oliveira; Elayne Heide; Carlos Brandt; Moacyr Rego; Maira Pitta; Ivan Pitta
Journal:  Cardiol Res       Date:  2014-12-04

Review 9.  Psoriasis and metabolic syndrome: implications for the management and treatment of psoriasis.

Authors:  J J Wu; A Kavanaugh; M G Lebwohl; R Gniadecki; J F Merola
Journal:  J Eur Acad Dermatol Venereol       Date:  2022-03-14       Impact factor: 9.228

Review 10.  Brodalumab for the Treatment of Psoriasis: A Review of Phase III Trials.

Authors:  Benjamin Farahnik; Kourosh Beroukhim; Michael Abrouk; Mio Nakamura; Tian Hao Zhu; Rasnik Singh; Kristina Lee; Tina Bhutani; John Koo
Journal:  Dermatol Ther (Heidelb)       Date:  2016-05-25
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.